William Feldman
@wbfeldman.bsky.social
Lung & ICU doctor | Faculty @harvardmed & @PORTAL_Research | Ethics Co-Chair @BrighamWomens
Reposted by William Feldman
New on FirstView: "Patent Thickets and Product Hops: Challenges and Opportunities for Legislative Reform" by @wbfeldman.bsky.social explains the strategies pharmaceutical manufacturers use to limit generic competition — and how to overcome them. #GenericDrugs
www.cambridge.org/core/journal...
www.cambridge.org/core/journal...
April 30, 2025 at 3:35 PM
New on FirstView: "Patent Thickets and Product Hops: Challenges and Opportunities for Legislative Reform" by @wbfeldman.bsky.social explains the strategies pharmaceutical manufacturers use to limit generic competition — and how to overcome them. #GenericDrugs
www.cambridge.org/core/journal...
www.cambridge.org/core/journal...
Reposted by William Feldman
Key message here is that there is actually little conflict between good care and the environment. The most effective asthma care is also best for the environment.
-reduces the need to use reliever medication
-reduces the number of acute exacerbations
www.nice.org.uk/news/article... #RespEd #LungSky
-reduces the need to use reliever medication
-reduces the number of acute exacerbations
www.nice.org.uk/news/article... #RespEd #LungSky
February 22, 2025 at 1:02 PM
Key message here is that there is actually little conflict between good care and the environment. The most effective asthma care is also best for the environment.
-reduces the need to use reliever medication
-reduces the number of acute exacerbations
www.nice.org.uk/news/article... #RespEd #LungSky
-reduces the need to use reliever medication
-reduces the number of acute exacerbations
www.nice.org.uk/news/article... #RespEd #LungSky
Our latest in @nejm.org on the dilemmas of treating patients with chronic lung disease.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
The Moral Injury of Inhaler Prescribing | NEJM
Many inhalers that are vital for patients with asthma or COPD are associated with
societal harms that can worsen the very diseases the products are designed to treat.
How can this dilemma be resolved?
www.nejm.org
February 22, 2025 at 12:47 PM
Our latest in @nejm.org on the dilemmas of treating patients with chronic lung disease.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Reposted by William Feldman
Physicians who receive money from inhaler manufacturers prescribe more inhalers in the future. New findings from Hasan Nadeem, @wbfeldman.bsky.social &co:
pubmed.ncbi.nlm.nih.gov/39937634/
pubmed.ncbi.nlm.nih.gov/39937634/
Association Between Industry Payments and Prescription of Inhaled Medications - PubMed
Association Between Industry Payments and Prescription of Inhaled Medications
pubmed.ncbi.nlm.nih.gov
February 14, 2025 at 2:03 AM
Physicians who receive money from inhaler manufacturers prescribe more inhalers in the future. New findings from Hasan Nadeem, @wbfeldman.bsky.social &co:
pubmed.ncbi.nlm.nih.gov/39937634/
pubmed.ncbi.nlm.nih.gov/39937634/
Reposted by William Feldman
United Health Group’s pharmacy benefit manager, Optum Rx, stopped covering Cole Schmidtknecht’s “life-changing” inhaler, suit alleges.
Man dies of asthma attack after inhaler cost skyrockets to more than $500
United Health Group’s pharmacy benefit manager, Optum Rx, stopped covering Cole Schmidtknecht’s ‘life-changing’ inhaler, suit alleges.
www.washingtonpost.com
February 10, 2025 at 10:58 PM
United Health Group’s pharmacy benefit manager, Optum Rx, stopped covering Cole Schmidtknecht’s “life-changing” inhaler, suit alleges.
Reposted by William Feldman
🔎 New in JAMA IM: Avik Ray, @wbfeldman.bsky.social & colleagues assess the comparative effectiveness of diabetes drugs in COPD patients.
They find GLP-1s & SGLT-2s are associated with lower risks of moderate or severe COPD exacerbations vs. DPP-4s during follow-up: jamanetwork.com/journals/jam...
They find GLP-1s & SGLT-2s are associated with lower risks of moderate or severe COPD exacerbations vs. DPP-4s during follow-up: jamanetwork.com/journals/jam...
February 11, 2025 at 4:12 PM
🔎 New in JAMA IM: Avik Ray, @wbfeldman.bsky.social & colleagues assess the comparative effectiveness of diabetes drugs in COPD patients.
They find GLP-1s & SGLT-2s are associated with lower risks of moderate or severe COPD exacerbations vs. DPP-4s during follow-up: jamanetwork.com/journals/jam...
They find GLP-1s & SGLT-2s are associated with lower risks of moderate or severe COPD exacerbations vs. DPP-4s during follow-up: jamanetwork.com/journals/jam...
Reposted by William Feldman
Democrats can win back some of the public’s trust by building an agenda around game-changing ideas *if* they address systemic issues like patent abuse at their root, rather than continuing to settle for legislation that is watered down and incremental at best. 1/8
🔗 www.nytimes.com/2025/02/01/o...
🔗 www.nytimes.com/2025/02/01/o...
February 5, 2025 at 12:05 AM
Democrats can win back some of the public’s trust by building an agenda around game-changing ideas *if* they address systemic issues like patent abuse at their root, rather than continuing to settle for legislation that is watered down and incremental at best. 1/8
🔗 www.nytimes.com/2025/02/01/o...
🔗 www.nytimes.com/2025/02/01/o...
Reposted by William Feldman
🚨 Just out today (online)! 🚨
Our results show that a common argument against #QALYs (based on the use of subgroup analyses) is not justified with empirical data.
With co-authors: @leah-rand.bsky.social , @wbfeldman.bsky.social, & @akesselheim.bsky.social from @portalresearch.org.
Our results show that a common argument against #QALYs (based on the use of subgroup analyses) is not justified with empirical data.
With co-authors: @leah-rand.bsky.social , @wbfeldman.bsky.social, & @akesselheim.bsky.social from @portalresearch.org.
January 31, 2025 at 8:11 PM
🚨 Just out today (online)! 🚨
Our results show that a common argument against #QALYs (based on the use of subgroup analyses) is not justified with empirical data.
With co-authors: @leah-rand.bsky.social , @wbfeldman.bsky.social, & @akesselheim.bsky.social from @portalresearch.org.
Our results show that a common argument against #QALYs (based on the use of subgroup analyses) is not justified with empirical data.
With co-authors: @leah-rand.bsky.social , @wbfeldman.bsky.social, & @akesselheim.bsky.social from @portalresearch.org.
Reposted by William Feldman
Treating COPD with DPI triple therapy had slightly lower exacerbation rates than with MDI triple therapy (about 7-9% lower). Better for patients, better for planet!
Mimms write up www.mims.co.uk/triple-inhal... and BMJ paper www.bmj.com/content/387/...
Mimms write up www.mims.co.uk/triple-inhal... and BMJ paper www.bmj.com/content/387/...
Triple inhalers in COPD: no outcome disadvantage with low-carbon option, study suggests
Patients using a triple combination dry powder inhaler had a slightly lower rate of COPD exacerbations than those using a high-carbon metered-dose inhaler, a retrospective study has found.
www.mims.co.uk
January 9, 2025 at 3:15 PM
Treating COPD with DPI triple therapy had slightly lower exacerbation rates than with MDI triple therapy (about 7-9% lower). Better for patients, better for planet!
Mimms write up www.mims.co.uk/triple-inhal... and BMJ paper www.bmj.com/content/387/...
Mimms write up www.mims.co.uk/triple-inhal... and BMJ paper www.bmj.com/content/387/...
Reposted by William Feldman
Dry powder inhaler shows similar effectiveness and safety to metered-dose inhaler, w numerous implications including that environmentally-friendly prescribing in this case is also clinically equivalent -- led by @wbfeldman.bsky.social of @portalresearch.org in BMJ: www.bmj.com/content/387/...
Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study
Objective To compare the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once daily dry powder inhaler,...
www.bmj.com
December 30, 2024 at 5:42 PM
Dry powder inhaler shows similar effectiveness and safety to metered-dose inhaler, w numerous implications including that environmentally-friendly prescribing in this case is also clinically equivalent -- led by @wbfeldman.bsky.social of @portalresearch.org in BMJ: www.bmj.com/content/387/...
I'm excited to share a new study out today in @bmj.com comparing the two single-inhaler triple therapies on the US market.
Brief thread below!
www.bmj.com/content/387/...
Brief thread below!
www.bmj.com/content/387/...
Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study
Objective To compare the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once daily dry powder inhaler,...
www.bmj.com
December 30, 2024 at 2:31 PM
I'm excited to share a new study out today in @bmj.com comparing the two single-inhaler triple therapies on the US market.
Brief thread below!
www.bmj.com/content/387/...
Brief thread below!
www.bmj.com/content/387/...
Reposted by William Feldman
Pre-holiday PPV: Fed Circuit in Teva v Amneal follows recommendation in amicus brief written by @wbfeldman.bsky.social and Sean Tu of @portalresearch.org, affirming delisting of improper inhaler patents from OB and helping promote timely generic competition: fedcircuitblog.com/wp-content/u...
fedcircuitblog.com
December 21, 2024 at 3:54 PM
Pre-holiday PPV: Fed Circuit in Teva v Amneal follows recommendation in amicus brief written by @wbfeldman.bsky.social and Sean Tu of @portalresearch.org, affirming delisting of improper inhaler patents from OB and helping promote timely generic competition: fedcircuitblog.com/wp-content/u...
Important win today for the generic drug industry and patients with asthma and COPD. The Federal Circuit ruled that Teva's patents on the delivery device of its ProAir HFA inhaler were impermissibly listed in the Orange Book.
patentlyo.com/patent/2024/...
patentlyo.com/patent/2024/...
Orange Book Device Patent Listings: Understanding Teva v. Amneal
by Dennis Crouch In a major decision clarifying the scope of Orange Book patent listings, the Federal Circuit has ruled …
patentlyo.com
December 20, 2024 at 10:05 PM
Important win today for the generic drug industry and patients with asthma and COPD. The Federal Circuit ruled that Teva's patents on the delivery device of its ProAir HFA inhaler were impermissibly listed in the Orange Book.
patentlyo.com/patent/2024/...
patentlyo.com/patent/2024/...
Reposted by William Feldman
The wrong ways and right ways to reform the FDA in the new administration - new in Health Affairs Forefront from me and Josh Sharfstein: www.healthaffairs.org/content/fore...
Will The New Administration’s FDA Be A Threat Or An Opportunity For The Public's Health? | Health Affairs Forefront
As various reform ideas are proposed, the organized medical and scientific community will need to work with the new leadership at the FDA to promote positive change–and oppose initiatives that undermi...
www.healthaffairs.org
December 13, 2024 at 3:14 PM
The wrong ways and right ways to reform the FDA in the new administration - new in Health Affairs Forefront from me and Josh Sharfstein: www.healthaffairs.org/content/fore...
Reposted by William Feldman
New Perspective in NEJM models the impact of recent proposals by USPTO and Congress to try to clear thickets of questionably innovative drug patents. Awesome graphics! With @portalresearch.org's Sean Tu, Bernard Chao, Ryan Whalen: www.nejm.org/doi/abs/10.1...
Clearing Dense Drug-Patent Thickets | NEJM
Proposed reforms from the U.S. Patent and Trademark Office and Congress could work in tandem to prevent patent thickets by targeting strategies that impede market entry of generic and biosimilar drugs.
www.nejm.org
December 2, 2024 at 12:49 PM
New Perspective in NEJM models the impact of recent proposals by USPTO and Congress to try to clear thickets of questionably innovative drug patents. Awesome graphics! With @portalresearch.org's Sean Tu, Bernard Chao, Ryan Whalen: www.nejm.org/doi/abs/10.1...
Some really interesting bits here on med non-adherence and the pharmaceutical supply chain. Definitely worth a listen for the latest on what Amazon pharmacy is up to.
Wishing you and your family a happy and healthy Thanksgiving!
I joined @thehowie.bsky.social and Dr Harlan Krumholz on their podcast, Health and Veritas, to discuss a wide ranging of topics in healthcare today.
Hope you’ll give it a listen! #medsky
insights.som.yale.edu/podcasts/hea...
I joined @thehowie.bsky.social and Dr Harlan Krumholz on their podcast, Health and Veritas, to discuss a wide ranging of topics in healthcare today.
Hope you’ll give it a listen! #medsky
insights.som.yale.edu/podcasts/hea...
Vin Gupta: Impact at Scale
Howie and Harlan are joined by Vin Gupta, a physician, a medical analyst for NBC News, and the chief medical officer of Amazon Pharmacy. Harlan reports on the Biden administration’s proposal to cover ...
insights.som.yale.edu
November 28, 2024 at 5:33 PM
Some really interesting bits here on med non-adherence and the pharmaceutical supply chain. Definitely worth a listen for the latest on what Amazon pharmacy is up to.
Reposted by William Feldman
New in JGIM: Dongzhe Hong & coauthors discuss the results of a physician survey on antibiotic prescribing preferences.
They find clinicians prioritize clinical outcomes over other factors like patient cost or risk of antibiotic resistance in deciding which antibiotic to prescribe. #idsky
They find clinicians prioritize clinical outcomes over other factors like patient cost or risk of antibiotic resistance in deciding which antibiotic to prescribe. #idsky
National Survey of Factors Associated with Physician Antibiotic Prescribing Preferences - Journal of General Internal Medicine
Background The development of new infectious disease therapies has become a public health priority given the suboptimal efficacy and adverse effects with current drugs for some patients. Understanding...
doi.org
November 26, 2024 at 3:57 PM
New in JGIM: Dongzhe Hong & coauthors discuss the results of a physician survey on antibiotic prescribing preferences.
They find clinicians prioritize clinical outcomes over other factors like patient cost or risk of antibiotic resistance in deciding which antibiotic to prescribe. #idsky
They find clinicians prioritize clinical outcomes over other factors like patient cost or risk of antibiotic resistance in deciding which antibiotic to prescribe. #idsky
Reposted by William Feldman
New from Dongzhe Hong, @wbfeldman.bsky.social, Metlay, Powers [@portalresearch.org]: Physicians considering new abx prioritize clear evidence of drug efficacy and safety over public health or econ factors like resistance or OOP costs: link.springer.com/article/10.1...
National Survey of Factors Associated with Physician Antibiotic Prescribing Preferences - Journal of General Internal Medicine
Background The development of new infectious disease therapies has become a public health priority given the suboptimal efficacy and adverse effects with current drugs for some patients. Understanding...
link.springer.com
November 26, 2024 at 1:45 PM
New from Dongzhe Hong, @wbfeldman.bsky.social, Metlay, Powers [@portalresearch.org]: Physicians considering new abx prioritize clear evidence of drug efficacy and safety over public health or econ factors like resistance or OOP costs: link.springer.com/article/10.1...
Reposted by William Feldman
New JAMA Special Communication from @ojwouters.bsky.social, Sean Tu, Matt Vogel and
@wbfeldman.bsky.social at @portalresearch.org: comparison of small molecule and biologic drugs show no clear rationale for greater legal protections for biologic drugs: jamanetwork.com/journals/jam...
@wbfeldman.bsky.social at @portalresearch.org: comparison of small molecule and biologic drugs show no clear rationale for greater legal protections for biologic drugs: jamanetwork.com/journals/jam...
Legal Protections for Biologics vs Small-Molecule Drugs in the US
This Special Communication analyzes and compares development times, clinical trial success rates, research and development costs, patent protection, market exclusivity periods, revenues, and treatment...
jamanetwork.com
November 26, 2024 at 3:46 AM
New JAMA Special Communication from @ojwouters.bsky.social, Sean Tu, Matt Vogel and
@wbfeldman.bsky.social at @portalresearch.org: comparison of small molecule and biologic drugs show no clear rationale for greater legal protections for biologic drugs: jamanetwork.com/journals/jam...
@wbfeldman.bsky.social at @portalresearch.org: comparison of small molecule and biologic drugs show no clear rationale for greater legal protections for biologic drugs: jamanetwork.com/journals/jam...
New paper out at @jamacurrent.bsky.social led by @ojwouters.bsky.social on the empirical assumptions underlying differential protection for biologics & small-molecule drugs.
Upshot: We found no good evidence supporting differential treatment by FDA (or under IRA).
jamanetwork.com/journals/jam...
Upshot: We found no good evidence supporting differential treatment by FDA (or under IRA).
jamanetwork.com/journals/jam...
Legal Protections for Biologics vs Small-Molecule Drugs in the US
This Special Communication analyzes and compares development times, clinical trial success rates, research and development costs, patent protection, market exclusivity periods, revenues, and treatment...
jamanetwork.com
November 25, 2024 at 5:10 PM
New paper out at @jamacurrent.bsky.social led by @ojwouters.bsky.social on the empirical assumptions underlying differential protection for biologics & small-molecule drugs.
Upshot: We found no good evidence supporting differential treatment by FDA (or under IRA).
jamanetwork.com/journals/jam...
Upshot: We found no good evidence supporting differential treatment by FDA (or under IRA).
jamanetwork.com/journals/jam...
We are hiring new fellows and faculty in PORTAL. Please reach out if interested! And spread the word.
📣PORTAL is hiring! 📣
There are less than 2 weeks left to apply for our Postdoctoral and General Medicine Fellowships, both with a focus on pharmaceutical law, health policy, and health services research. Apply by December 1, 2024.
Learn more: mailchi.mp/3e02f38a708b/portal-hiring-2025
There are less than 2 weeks left to apply for our Postdoctoral and General Medicine Fellowships, both with a focus on pharmaceutical law, health policy, and health services research. Apply by December 1, 2024.
Learn more: mailchi.mp/3e02f38a708b/portal-hiring-2025
Deadline Approaching - Join the PORTAL Team!
Apply by December 1, 2024 to be a PORTAL Postdoctoral or General Medicine Fellow. We are also accepting applications for a Faculty Member in Health Policy or Health Services Research.
mailchi.mp
November 21, 2024 at 5:36 PM
We are hiring new fellows and faculty in PORTAL. Please reach out if interested! And spread the word.
Reposted by William Feldman
🎙️New NEJM audio interview recapping where we are with Medicare price negotiation and how to think about the results from the first 10 drugs.
#healthpolicy #medsky @portalresearch.bsky.social
www.nejm.org/do/10.1056/N...
#healthpolicy #medsky @portalresearch.bsky.social
www.nejm.org/do/10.1056/N...
Interview with Benjamin Rome on the results of the initial round of drug-price negotiation under the Inflation Reduction Act. | NEJM
Audio Interview from the New England Journal of Medicine — Interview with Benjamin Rome on the results of the initial round of drug-price negotiation under the Inflation Reduction Act.
www.nejm.org
November 21, 2024 at 3:08 PM
🎙️New NEJM audio interview recapping where we are with Medicare price negotiation and how to think about the results from the first 10 drugs.
#healthpolicy #medsky @portalresearch.bsky.social
www.nejm.org/do/10.1056/N...
#healthpolicy #medsky @portalresearch.bsky.social
www.nejm.org/do/10.1056/N...
I'm very much looking forward to serving on a panel at this event hosted by the FDA and Center for Research on Complex Generics focused on the transition to lower emission inhaler propellants. Registration still open!
www.complexgenerics.org/education-tr...
www.complexgenerics.org/education-tr...
Navigating the Transition to Low Global Warming Potential Propellants - The Center for Research on Complex Generics (CRCG)
Co-hosts: FDA and the Center for Research on Complex Generics (CRCG) In person (at The Universities at Shady Grove; Rockville, MD) and virtual workshop.
www.complexgenerics.org
November 21, 2024 at 1:28 PM
I'm very much looking forward to serving on a panel at this event hosted by the FDA and Center for Research on Complex Generics focused on the transition to lower emission inhaler propellants. Registration still open!
www.complexgenerics.org/education-tr...
www.complexgenerics.org/education-tr...
Reposted by William Feldman
Check out the new NEJM audio interview with @bnrome.bsky.social about the outcomes and future prospects of Medicare drug price negotiation under the Inflation Reduction Act after 1 year - from @portalresearch.bsky.social: www.nejm.org/do/10.1056/N...
Interview with Benjamin Rome on the results of the initial round of drug-price negotiation under the Inflation Reduction Act. | NEJM
Audio Interview from the New England Journal of Medicine — Interview with Benjamin Rome on the results of the initial round of drug-price negotiation under the Inflation Reduction Act.
www.nejm.org
November 21, 2024 at 12:42 AM
Check out the new NEJM audio interview with @bnrome.bsky.social about the outcomes and future prospects of Medicare drug price negotiation under the Inflation Reduction Act after 1 year - from @portalresearch.bsky.social: www.nejm.org/do/10.1056/N...